Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC 17 December 2025
CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights 04 November 2025
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights 04 November 2025
